BRAIN Biotech AG (HAM:BNN) Other Financing: €0.00 Mil (TTM As of Mar. 2026)


HAM:BNN BRAIN Biotech AG HAM:BNN
66 GF Score
Price €2.72
GF Value €2.48
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BRAIN Biotech AG Other Financing?

BRAIN Biotech AG HAM:BNN -0.73% 66 Other Financing is €0.00 Mil as of Mar. 2026. GuruFocus rates HAM:BNN with a GF Score™ of 66/100 and a GF Value™ of €2.48 (Fairly Valued). The stock has 2 warning signs investors should review.

BRAIN Biotech AG's Other Financing for the three months ended in Mar. 2026 was €0.00 Mil.

BRAIN Biotech AG's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

BRAIN Biotech AG Other Financing Historical Data

* Premium members only.

The historical data trend for BRAIN Biotech AG's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG Other Financing Chart

BRAIN Biotech AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.59 0.00 -9.59 0.60 -1.70

BRAIN Biotech AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HAM:BNN
66GF Score
BRAIN Biotech AG HAM:BNN
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BRAIN Biotech AG Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0.00 Mil mean?
BRAIN Biotech AG (HAM:BNN) has a Other Financing of €0.00 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for BRAIN Biotech AG and its competitors.
Is BRAIN Biotech AG's Other Financing too high?
BRAIN Biotech AG's current Other Financing is €0.00 Mil. Overall, BRAIN Biotech AG has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Other Financing compare to LIN and SHW?
BRAIN Biotech AG's Other Financing of €0.00 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Chemicals company?
A good Other Financing depends on the Chemicals industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current Other Financing is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.48, compared to a current price of €2.72 — trading 9.7% above its estimated fair value. The current Other Financing is €0.00 Mil. BRAIN Biotech AG's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Other Financing is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.72 is trading 9.7% above its estimated GF Value™ of €2.48. GuruFocus considers BRAIN Biotech AG to be Fairly Valued.

Key valuation signals for HAM:BNN:

  • Other Financing: €0.00 Mil
  • GF Value™: €2.48 vs. price of €2.72 (9.7% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRAIN Biotech AG Business Description

Other Exchanges 0RFI:UKBNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
66GF Score

Get the complete analysis for HAM:BNN

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.72
Price
€2.48
GF Value